[Monitoring of patients using atypical psychotics and screening for metabolic syndrome].
Legrix
Dorothée
D
EPSM Lille-Métropole. dlegrix@epsm-lille-metropole.fr
D018687:Antidepressive Agents, Second-Generation / Q000009:adverse effects*; D001714:Bipolar Disorder / Q000150:complications / Q000188:drug therapy*; D002318:Cardiovascular Diseases / Q000209:etiology; D003924:Diabetes Mellitus, Type 2 / Q000209:etiology; D016903:Drug Monitoring / Q000379:methods*; D005602:France; D006801:Humans; D008019:Life Style; D008403:Mass Screening / Q000379:methods*; D024821:Metabolic Syndrome / Q000139:chemically induced / Q000175:diagnosis / Q000517:prevention & control; D009765:Obesity / Q000209:etiology; D040242:Risk Reduction Behavior; D012559:Schizophrenia / Q000150:complications / Q000188:drug therapy*
D018687:Antidepressive Agents, Second-Generation